Prevention (HAV)

Targeted Vaccine Strategy Best

Published in Vaccine Weekly, February 2nd, 2000

A study from Ireland suggests that hepatitis A prevention efforts are most cost-effective when a targeted vaccination approach is used.

Researcher E. Rajan and colleagues of Dublin's Mater Private Hospital report that vaccination is appropriate when hepatitis A virus (HAV) immunity within a given population is 45% or less.

They reported the findings in the American Journal of Gastroenterology (Cost-effective analysis of hepatitis A prevention in Ireland," American Journal of Gastroenterology, January 2000;95(1):223-226).

"The purpose of this study was to determine the most cost-effective prevention strategy against...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry